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Abstract
Rare copy number variants (CNVs) are frequently associated with common neurological disorders such as mental
retardation (MR; learning disability), autism, and schizophrenia. CNV screening in clinical practice is limited because
pathological CNVs cannot be distinguished routinely from benign CNVs, and because genes underlying patients’
phenotypes remain largely unknown. Here, we present a novel, statistically robust approach that forges links between 148
MR–associated CNVs and phenotypes from ,5,000 mouse gene knockout experiments. These CNVs were found to be
significantly enriched in two classes of genes, those whose mouse orthologues, when disrupted, result in either abnormal
axon or dopaminergic neuron morphologies. Additional enrichments highlighted correspondences between relevant
mouse phenotypes and secondary presentations such as brain abnormality, cleft palate, and seizures. The strength of these
phenotype enrichments (.100% increases) greatly exceeded molecular annotations (,30% increases) and allowed the
identification of 78 genes that may contribute to MR and associated phenotypes. This study is the first to demonstrate how
the power of mouse knockout data can be systematically exploited to better understand genetically heterogeneous
neurological disorders.
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Introduction
Mental retardation (MR) is defined as an overall intelligence
quotient lower than 70, and is associated with functional deficits in
adaptive behaviour, such as daily-living skills, social skills and
communication. This disorder affects 1%–3% of the population
and results from extraordinarily heterogeneous environmental and
genetic causes [1]. Genetic changes underlying MR are still poorly
resolved, especially for the autosomes that provide the largest
contribution to disease aetiology [2]. Microscopically visible
chromosomal rearrangements detected by routine chromosome
analysis are the cause for MR in ,5%–10% of patients [3]. Such
rearrangements represent gains or losses of more than 5–10 Mb of
DNA and affect many genes thereby almost inevitably leading to
developmental abnormalities during embryogenesis. The most
common effect of these variants is cognitive impairment, but they
can also be frequently associated with other abnormalities such as
heart defects, seizures and dysmorphic features [4].
Many recent genomic microarray studies have indicated that
smaller, submicroscopic rearrangements, such as copy number
variations (CNVs), frequently underlie MR (Table S1). However,
CNVs, defined as DNA deletions or duplications greater than
1 Kb [5], are also widespread in the general population which
considerably hinders the clinical interpretation of patients’ CNVs
[6]. Until now, most clinical CNV studies have focused on the
identification of rare de novo CNVs [7–9], as the rate of de novo large
(.50 kb) CNVs in the general population is comparatively low
[10,11]. Nevertheless, discriminating between benign and patho-
genic CNVs solely on the basis of size and lack of inheritance is
crude and provides no insights into how CNVs exert their
phenotypic effects.
Fortunately, the genomics era has amassed a wealth of data that
have long promised to associate the disruption of a particular
molecular function or cellular pathway with clinical observations;
in short, to forge links between genotype and disease phenotype.
These genomic data include behavioural, physiological and
anatomical examinations following the disruption of more than
5000 individual mouse genes [12–14]. These mouse phenotypic
measurements more closely resemble observations from human
clinical examination than any other systematic genome-wide data
source. They might be especially relevant to human gene deletion
variants, which represent a large majority among the rare disease-
associated CNVs considered here (Table 1 and Table S2).
Available genomic data also include functional annotations such
as from the Gene Ontology resource [15], tissue expression levels
[16] and carefully curated pathway data such as the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [17].
Our approach was to test the null hypothesis that genes present
in MR–associated CNVs randomly sample all human genes. In
particular, are they a random sample of genes (i) that, when
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disrupted in mice, result in particular phenotypes, or (ii) that are
predominantly expressed in the human brain, or (iii) that
participate in specific human disease pathways? To ensure that
we correctly account for the application of multiple tests, we have
controlled the false discovery rate (FDR) [18] such that there is
only a small 5% likelihood that any annotation term has been
identified as over-represented in our tests simply by chance. Only
if any particular set of genes present within MR–associated CNVs
form a significantly (FDR,5%) non-random sample can we be
truly justified in predicting single genes, among the dozens
commonly overlapped by such CNVs, as contributing to MR
disease aetiology. In this study, we show both significant and
substantial enrichments in phenotypic annotations whose power in
predicting pathoetiology greatly exceeds that of molecular
annotations.
Results
For this study, 148 MR–associated rare CNVs collated from a
variety of sources (Table S1) were merged to obtain a set of 112
distinct non-overlapping CNV regions (CNVRs) and partitioned
according to the direction of copy number change (Gain or Loss).
We also collated a control set of 26,472 benign CNVs (1,388
CNVRs) from previous publications (see Materials and Methods).
MR–associated CNVs are most obviously distinguished from
benign CNVs by their large sizes and by their larger numbers of
copy number losses (n=111, 75%) relative to gains (n=37, 25%)
(Table 1). These differences remained even when comparing
benign and MR CNVs detected by the same platform (tiling
resolution 32 k BAC arrays): the median size of 40 MR CNVs is
approximately twice that of benign CNVs (1.6 Mb versus 0.85 Mb)
while 58.6% of benign CNVs on this platform are losses. This
increased bias towards loss CNVs would be expected if the MR
phenotypes considered here result either from haploinsufficiency
or from recessive deleterious mutations being revealed in the
remaining haplotype. There is only a small difference (17.6%)
between the average gene densities of MR–associated and benign
CNVs (Table 1). Consequently, we need to look to gene function,
rather than gene numbers, when attempting to differentiate
disease-associated from benign CNVs.
Nervous system phenotypes and expression
We first tested whether MR–associated CNVR genes were
enriched in 33 major categories of mouse phenotypes (see
Materials and Methods). Although for All MR–associated CNVRs
none of these terms was significant, the set of Loss MR–associated
CNVRs showed a strong and significant enrichment in genes
whose knockouts in mice produced a nervous system phenotype
(+13.6%, or 1.14-fold, enrichment, p=361023, FDR,5%;
Figure 1). An enrichment of genes associated with nervous system
phenotypes was not observed within the Gain CNVRs (+0.2%).
Given the significant enrichment within the Loss set, we then
tested this set against each of 147 finer-scale mouse nervous system
phenotypes. Two of these terms were significantly enriched
(FDR,5%): abnormal axon morphology (obs=19, exp=7.1,
+170% enrichment, p=361025), and abnormal dopaminergic
neuron morphology (obs=9, exp=2.5, +260% enrichment,
p=361024) (Figure 1). Both of these mouse neural phenotypes
are relevant to human MR phenotypes owing to these mouse
phenotype’s abnormalities in neuronal and cerebral cortex
morphologies (see Discussion). Within Gain CNVRs, we observe
a non-significant enrichment of genes associated with abnormal
axon morphology (obs=6, exp=2.7, +120% enrichment,
p=561022) but a non-significant depletion of genes associated
with abnormal dopaminergic neuron morphology (obs=0,
exp=0.95, 2100% deficit, p=0.38).
The neurological phenotypes of MR patients suggested that
MR–associated CNVs might contain an unusually high density of
genes that, when mutated, are involved in human neurological
disease. Considering those genes classified by KEGG to be
involved in 6 neurodegenerative pathways, we indeed found MR–
associated CNVRs to be significantly enriched in genes involved in
the Parkinson’s disease pathway (obs=8, exp=2.7, +196%
enrichment, p=361023, FDR,5%; Figure 2). While enrichments
of this pathway’s genes were observed both for Loss CNVRs
(obs=7, exp=2.1, +230% enrichment, p=361023, FDR,5%)
and for Gain CNVRs (obs=2, exp=0.8, +151% enrichment,
Table 1. Genomic extent and NCBI gene content for MR–associated and benign CNVs.
CNVR number
(median size)
CNV number
(median size)
Gene
Count
MR CNV genes also
contained within benign
CNVs
MR CNV genes not
contained within benign
CNVs
Genome
covered (Mb) Gene density/Mb
All MR 112 (2.76 Mb) 148 (2.74 Mb) 4,009 703 3,397 440.1 9.1
Gain MR 32 (1.90 Mb) 37 (2.55 Mb) 1,189 283 907 92.9 12.8
Loss MR 85 (3.04 Mb) 111 (2.85 Mb) 3,159 449 2,711 367.8 8.6
Benign 1,388 (0.17 Mb) 26,472 (0.21 Mb) 4,576 N/A N/A 429.0 10.7
doi:10.1371/journal.pgen.1000531.t001
Author Summary
Mental retardation (MR; also known as learning disability)
affects 1%–3% of people and is often associated with the
presence of genomic copy number variations (CNVs) such
as deletions and duplications. Most of these CNVs are rare
and they often involve tens, sometimes hundreds, of
genes. Pinpointing exactly which particular gene or genes
are responsible for MR in an individual patient is therefore
challenging and limits diagnostic applications. In this
study, the functions of genes present within a large
collection of MR–associated CNVs were investigated by
comparing them to data from large-scale mouse knock-out
experiments. We found that MR–associated CNVs contain
greater than expected numbers of genes that give specific
nervous system phenotypes when disrupted in the mouse.
Not only does this study confirm that CNVs frequently
cause MR, but it narrows down the list of genes whose
changes lead to this disorder from thousands to several
dozen. This reduced list of genes brings wide-spread
genetic testing for MR one step closer. It also provides a
better understanding of the biology behind MR that could,
eventually, yield medical treatments.
Linking Mouse Models to MR-Associated CNVs
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p=0.19), significance was reached only for Loss CNVRs. As
Parkinson’s disease is a condition characterized by the degener-
ation and dysfunction of dopaminergic neurons [19], these
enrichments corroborate our finding that orthologues of genes
whose disruption in mouse gives rise to abnormal dopaminergic
neuron morphology are enriched in MR–associated CNVRs (see
above).
The allelic changes underlying MR phenotypes might also be
expected to preferentially involve ‘brain-specific’ genes, those that
are highly expressed in the human brain relative to other human
tissues. Indeed, All MR–associated CNVRs were significantly
enriched in brain-specific genes (+24% enrichment, p=161022;
Figure 3), specifically for Loss (+31% enrichment, p=861023) but
not for Gain CNVs (+4% enrichment, p=0.45). The significant
enrichments observed when testing mouse phenotypes are thus
corroborated by enrichments in human gene expression.
Distinction from benign CNVs
These findings would have little or no predictive potential if
apparently ‘benign’ CNVs (those present in the general human
population) also exhibit such biases. However, in contrast to the
above results, benign CNVs show no significant enrichments of (i)
genes that are highly-expressed in the brain (211% deficit, p=0.2;
Figure 3), (ii) genes present in neurodegenerative disease pathways
(232% deficit, p=0.1; Figure 2), or (iii) genes with nervous system
phenotypes when disrupted in mice (211% deficit, p=0.01;
Figure 1). Instead, benign CNV genes show significant tendencies
to encode proteins with roles in immunity and host defense
[20,21]. Each of these three features thus may be exploited to
distinguish MR–associated CNVR genes from benign CNVR
genes.
MR–associated and benign CNVs show no significant tendency
to overlap (p=0.1). Nevertheless, by excluding all genes in MR–
associated CNVs whose gain/loss-matched copy number change is
also seen in benign CNVs we enhanced the discrimination of
genes whose copy number change is predicted to contribute to
MR aetiology. This was specifically the case for mouse fine-scale
nervous system phenotypes and human neurodegenerative disease
pathways (Figure 1 and Figure 2). Moreover, after excluding
benign CNV-overlapped genes, not only Parkinson’s disease
pathway genes, but genes from 5 other neurodegenerative disease
pathways (namely, Alzheimer’s disease, Amyotrophic Lateral
Sclerosis, Huntington’s disease, Dentatorubropallidoluysian atro-
phy and Prion Diseases) when considered together, became
significantly enriched (+60% enrichment; p=0.02) in this analysis.
These results would be explained if MR-causative alleles segregate
more with sequence that is copy number variable in MR
individuals than with CNVs observed in the general population.
Additional clinical features
We considered whether our method could identify significant
associations between mouse and human patient phenotypes other
than MR. We investigated 7 clinical features that were present in
our patient population in addition to the MR phenotype, namely
brain-, cleft palate-, eye-, facial-, heart- or urogenital- abnormal-
ities and seizures (see Materials and Methods). We tested whether
CNVs from individuals with these specific clinical features were
significantly enriched in genes associated with phenotypically-
relevant mouse phenotypes. In order to limit the large number of
statistical tests that could be performed we matched mouse
phenotype categories (each containing between 129 and 220
terms) to each of the 7 clinical features based on clinical experience
(see Materials and Methods) before performing the association
tests. We found that 4 of the 7 additional clinical features were
significantly associated (FDR,5%) with between 1 and 6 mouse
phenotypic terms (Figure 4). For example, the CNVRs of the 8
MR patients presenting with cleft palate were significantly
enriched with genes whose mouse orthologues, when disrupted,
also exhibited cleft palate (Figure 4). Importantly, no significant
associations were observed between CNVs from humans without a
Figure 1. Enrichments of MGI phenotype terms among genes overlapped by MR–associated CNVRs. One phenotypic category (Nervous
System) and two specific nervous system phenotypes (Abnormal Axon Morphology and Abnormal Dopaminergic Neuron Morphology) are
significantly over-represented in genes overlapped by All or Loss-only MR–associated CNVRs. The phenotypes result from the disruption of mouse
genes that have been mapped to their unique human orthologue. MR CNVR sets denoted ‘‘minus benign CNVs’’ have had genes removed that are
also overlapped by benign CNVRs when matched on the direction of copy number change (i.e. Gain or Loss). Columns marked with an asterisk (‘‘*’’)
are significantly enriched (FDR,5%).
doi:10.1371/journal.pgen.1000531.g001
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particular clinical feature apart from MR and any mouse
phenotype category matched to patients with that clinical feature,
with the notable exception of ‘abnormal axon morphology’ that
thus appears to be a term of broad relevance to the primary MR
Figure 2. Human gene enrichments corroborate mouse phenotypic enrichments. (A) Enrichments of genes involved in Parkinson’s disease
or human neurodegenerative disease pathways that are overlapped by MR–associated CNVRs. These genes are described by KEGG as belonging to
the Parkinson’s disease pathway (HSA05020) or belonging to any of six neurodegenerative pathways (namely, HSA05010, HSA05020, HSA05030,
HSA05040, HSA05050, and HSA05060). MR–associated CNVR sets denoted ‘‘minus benign CNVs’’ have had genes removed that are also overlapped
by benign CNVRs showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping MR–associated CNVR. Columns marked
with an asterisk (‘‘*’’) are significantly enriched (FDR,5%). (B) All genes contained in the KEGG Parkinson’s disease pathway (HSA05020). Of the 18
genes in this pathway, 8 (highlighted in red) are involved in a rare de novo CNV from at least one or more patients. The remaining genes (depicted in
grey) lie outside of the 148 MR CNVs that we considered.
doi:10.1371/journal.pgen.1000531.g002
Linking Mouse Models to MR-Associated CNVs
PLoS Genetics | www.plosgenetics.org 4 June 2009 | Volume 5 | Issue 6 | e1000531
presentation (Figure 4). These findings demonstrate the relevance
of mouse gene knockout observations to both the MR phenotype
and associated phenotypes in patients.
Predicting genetic etiology
The distinctions between MR–associated and benign CNVR
genes, described above, allowed the identification of genes whose
copy number change may contribute to MR and associated
phenotypes. To identify such candidate genes, we could not
exploit Gene Ontology annotations (Figure S1) or brain expression
enrichments (Figure 3) as these enrichments provide insufficient
discriminatory power (,30% increase over expected). Of the
4,009 genes present in the 148 MR–associated CNVs, 55 are
annotated with either a mouse knockout phenotype (n=29) and/
or a neurodegenerative disease pathway (n=29) that was
significantly over-represented in MR–associated Loss CNVRs
(Table 2). 50 of the MR–associated CNVs (33%) contain at least
1 of these 55 candidate genes. We calculate that our list represents
a ,120% increase of likely phenotype-contributing genes over the
random expectation (see Materials and Methods). Similarly, 34
genes were identified as potential candidates for additional clinical
features such as cleft palate, facial or brain abnormalities, or
seizures, 23 of which were not associated with MR itself (Table 2).
We note that whilst some of these candidate genes might have
been prioritized from among the 4,009 CNVRs genes using a priori
subjective expectations, our method is the first to generate a
candidate gene set on the basis of objective and statistically sound
criteria.
Discussion
If de novo MR–associated CNVs do not contribute to disease
etiology their gene contents would not be expected to exhibit
biases in gene function or expression. Instead, we demonstrate the
first evidence for significant tendencies of MR–associated CNV
genes to be brain-expressed, to belong to neurodegenerative
pathways, and to present particular phenotypes when disrupted in
mice, all of which validate the assumption that large de novo CNVs
commonly underlie MR phenotypes. These results could not have
been obtained without collating data from a number of sources.
For example, essentially all (147 of 148) CNVs were required to
obtain a significant enrichment of genes whose mouse orthologues’
knockout produced a nervous system phenotype (Figure S2). It was
only by harnessing the statistical power of a research community’s
large data set that this meta-analysis achieved significance of
statistical associations (see Materials and Methods).
The significant signals seen in Loss CNVs, but not in Gain
CNVs, imply that MR phenotypes commonly result from gene
dosage sensitivity (haploinsufficency). However, we cannot dis-
count that they may occur from the uncovering, by DNA loss, of
rare recessive alleles. While we did not observe an enrichment
within the Gain CNVRs of genes associated with abnormal
dopaminergic neuron morphology or of genes that showed brain-
specific expression, we did observe non-significant enrichments of
genes associated with abnormal axon morphology and of
Parkinson’s disease pathway genes. Given that the Gain CNVRs
overlap 38% of the number of genes overlapped by the Loss
CNVRs (Table 1), it is plausible that these enrichments might
reach significance as more Gain MR–associated CNVs are
reported and analysed.
Our results are in contrast with previously-reported sporadic
and familial cases of MR whose associated genes are enriched in
both X-chromosome location and enzymatic function [22].
Nevertheless, this is explained by Wright’s physiological theory
of dominance: haplosufficient genes, such as those lying on the X
chromosome, have an expected tendency to encode enzymes,
whereas haploinsufficient genes, such as those expected to underlie
our autosomal MR disorders, have an expected tendency to
encode transcription regulatory genes [23]. Indeed, we do observe
a significant enrichment of genes associated with transcriptional
regulation within MR–associated CNVRs (Figure S1). In contrast
to X-linked MR genes, of which approximately one quarter
encode postsynaptic proteins [24], we observe a small and non-
significant depletion (p=0.39) of postsynaptic protein genes among
our MR–associated CNVs.
None of the human CNVs recorded in this study represent
homozygous losses. Thus it may initially appear problematic to
compare human phenotypes directly with those from mice
harbouring homozygous gene disruptions. Nevertheless, without
sequence information confirming the genetic integrity of the
Figure 3. Enrichment of genes, overlapped by MR–associated CNVRs, that are expressed highly in the brain relative to other-tissue
(brain-specific genes). Such genes are defined as those whose level of expression in the brain exceeds 4 times the median expression level in all
other tissues (see Materials and Methods). MR–associated CNVR sets denoted ‘‘minus benign CNVs’’ have had genes removed that are also
overlapped by benign CNVRs showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping MR–associated CNVR. Columns
marked with an asterisk (‘‘*’’) are significantly enriched (FDR,5%).
doi:10.1371/journal.pgen.1000531.g003
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surviving haplotype we cannot be certain that these human
hemizygous loss CNVs do not contain independent disruptions of
each allelic copy. To gain some insight into this issue we
considered 21 of the 55 candidate genes that contribute to a
significantly enriched mouse knock-out phenotype identified in our
study (Table 2), and whose phenotype has been recorded in the
MGI resource when in the hemizygous state. Of these 21, four
(namely, En1, Mn1, Plp1 and Pmp22) also exhibit the phenotype of
interest when hemizygously disrupted [25–28]. Of the remaining
17 genes, all exhibit abnormal phenotypes, and thus are
haploinsufficient, with the exceptions of Mapt and Slc6a3 [29,30].
Importantly, these mouse hemizygous phenotypes are often
closely-related to the homozygous phenotypes, while some
hemizygous phenotypes appear particularly relevant to the
associated human phenotype. For example, Scn1a (which contrib-
utes to the tremors phenotypic enrichment we find to be associated
with patients presenting with seizures) exhibits a seizures
phenotype when in the hemizygous state in mice [31].
Does our analysis allow us to link particular mouse gene
knockout phenotypes to human CNV phenotypes? Obviously, a
direct comparison between mouse neural phenotypes and human
MR phenotypes is hindered because the invasive procedures of
brain biopsies in patients are unacceptable. Results from a limited
number of post-mortem studies of MR patients suggest that
abnormalities of dendritic spines are a general neuropathological
feature of MR [32]. The mouse gene knockout phenotypes do
provide a plausible explanation for the brain phenotypes observed
in some patients as a consequence of the structural variation
identified in their genomes. An example of this is the myelin-
associated glycoprotein (MAG) gene that is deleted in one patient
Figure 4. Enrichments of MGI phenotype terms for genes overlapping secondary clinical feature-grouped CNVRs. 5 secondary
feature-grouped CNVs revealed between 1–6 significantly enriched phenotypic terms (Cleft Palate, panels (A) to (F); Facial abnormality, panel (G);
Brain Abnormality, panels (H) and (I); Seizures, panel (J)). These MGI terms are significantly over-represented in genes overlapped by All or Loss-only
secondary feature-grouped CNVRs (see main text). The phenotypes result from the disruption of mouse genes that have been mapped to their
unique human orthologue. MR CNVR sets denoted ‘‘minus benign CNVs’’ have had genes removed that are also overlapped by benign CNVRs
showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping MR–associated CNVR. Columns marked with an asterisk (‘‘*’’)
are significantly enriched (FDR,5%).
doi:10.1371/journal.pgen.1000531.g004
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Table 2. Candidate genes for MR and associated clinical features.
MGI phenotype or KEGG pathway Gene in Loss MR CNVR Gene in Gain MR CNVR
- associated with Mental Retardation
Abnormal dopaminergic neuron morphology (MP0003243) EN1 LOC390992 SLC6A3
HES1 MAPK10 SNCA
KCNJ6 SLC18A2 SPP1
Abnormal axon morphology (MP0005404) APG5L MAPT PTPN13 LGI4
ARSA MBP SCN1B MAG
CLCN6 MFN2 SIM1 SCN1B
LEPR NEFH SNCA SCYL1
LGI4 NR2F1 TYROBP TYROBP
MAG PLP1 ZIC5
MAN2B1 PMP22
KEGG Neurodegenerative Pathway genes ALS2 HSPD1 RERE APLP1
APLP1 MAPT SNCA* BAD
BACE2 NCOR1 SOD1 CLTCL1
CAGLP NEFH SSR4 CREBBP
CASP7 PARK7* STX1A* HADH2
CASP8 PEN2 UBB* PEN2
CLTB PNUTL1* UBE2J2* PNUTL1
CLTCL1 RAC1 UBE2L3* UBE1*
HD
- associated with Brain Abnormality
Abnormal myelination (MP0000920) HPN OLIG2 HPN
LGI4 PLP1 LGI4
MAG TYROBP MAG
TYROBP
Abnormal axon morphology (MP0005404) LGI4 PLP1 LGI4
MAG SCN1B MAG
MAPT TYROBP SCN1B
NR2F1 TYROBP
- associated with Cleft Palate
Abnormal basisphenoid bone morphology (MP0000106) DISP1 DLX2
DLX1
Cleft palate (MP0000111) DLX1 GAD1 CREBBP
DLX2 LHX8
EDNRA MN1
Abnormal maxilla morphology (MP0000455) DLX1 EDNRA
DLX2 GAD1
Abnormal alisphenoid bone morphology (MP0003235) DLX1 EDNRA
DLX2
Absent stapedial artery (MP0004666) DLX1 DLX2
Abnormal palatine bone morphology (MP0005249) DLX1 LHX8
DLX2 MN1
EDNRA
- associated with Facial Dysmorphism
Abnormal zygomatic arch morphology (MP0004469) ACVR1 TBX1 IDUA
CHRD ZMPSTE24 NFATC2
IDUA TBX1
- associated with Seizures
Tremors (MP0000745) ATF2 KCNAB2 SELE
EN1 KCNJ6 SELP
Linking Mouse Models to MR-Associated CNVs
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(case 123, Table S2) and duplicated in another (case 124), whilst
the knockout of its orthologous gene in mice leads to both
abnormal axon morphology and tremors phenotypes [33].
Underexpression of MAG in transfected Schwann cells is known
to lead to hypomyelinisation [34]. Therefore, the delayed brain
myelinisation observed in the patient with the MAG deletion could
be caused by under-expression of MAG during brain development.
By contrast, over-expression of MAG is known to lead to
accelerated myelinisation [35]. Whether the macrocephaly in the
patient with the MAG duplication is related to over-expression of
MAG during brain development remains unknown.
Our enrichment analysis revealed 8 genes associated with cleft
palate in humans, present in 6 different patients (cases 10, 13, 27,
48, 96, and 141). Seven of these genes were located in Loss CNVs
on human chromosomes 1p31.1p31.3 (containing LHX8),
1q41q42.13 (DISP1), 2q24.3q31.1 (DLX1, DLX2 and GAD1),
4q31.21q31.23 (EDNRA) and 22q12.1 (MN1), and one with a Gain
CNV on human chromosome 16p13.2–p13.3 9 (CREBBP). Except
for DISP1, all these genes have been associated with cleft palate in
mouse models [26,36–39], whereas only LHX8 and GAD1 have
been associated with cleft palate disorders in humans [40,41]. This
strongly suggests that our approach revealed 6 novel orofacial cleft
(OFC) candidate genes in humans. Strikingly, the hemizygous loss
of five of these OFC candidate genes may also contribute to MR.
Absence of both Dlx1 and Dlx2 in mice results in abnormal
differentiation within the forebrain [36,42]. Both genes also
regulate Arx, a homeobox transcription factor required for the
migration of interneurons, whose human equivalent ARX, when
mutated, is associated with X-linked MR and epilepsy [43]. In
addition, mutations and deletions of CREBBP causes the
Rubinstein-Taybi syndrome which is characterized by MR [44].
Ednra is involved in cranial neural crest cell migration from the
posterior midbrain and hindbrain to the arches [45]. Lhx8 is
required for the development of many cholinergic neurons in the
mouse forebrain [46], whereas GAD1, which encodes the GABA-
producing enzyme, may play a role in the development and
plasticity of the central nervous system [39]. In conclusion, it
appears that our approach identified a large number of interesting
and plausible novel candidate genes for both MR and associated
clinical phenotypes.
Mouse phenotype data have not previously been exploited in a
systematic genome-wide analysis, and our results clearly show its
utility in addressing a particularly difficult and contemporary
challenge in the field of neurological genomic disorders. The
functional biases we see for MR–associated CNV genes can now
be exploited to prioritise genes for further investigation in MR
individuals without large de novo CNVs (Table 2). We suggest that
all human genes whose orthologues present specific phenotypes
when disrupted in mice (Figure 1) deserve particular scrutiny for
fine-scale insertion, deletion or point mutations contributing to
MR. Mouse orthologue knockout data are available currently for
only ,25% of all human genes. More specifically, of the 4,009
genes overlapped by the MR–associated CNVs considered here,
830 (,21%) have available phenotypic annotations. Thus, we
would expect that many more candidate genes possessing these
annotations will be discovered within MR–associated CNVs as
further knockouts are generated. Furthermore, we consider all
genes that are involved in the specific molecular pathways we have
identified, such as Parkinson’s disease and other neurodegenera-
tive disorder pathways, to represent candidates for MR and/or
associated phenotypes when hemizygous. We propose that the
contribution of these candidate genes (Table 2) to many MR
phenotypes can now be investigated thoroughly in mouse model
systems: specifically, the 55 genes whose hemizygous deletions may
be associated with MR are now amenable to study using
hemizygous knockout mouse models.
Our study has exploited CNVs identified using several different
platforms. As the identification technologies have improved,
CNVs called using earlier technologies have been shown to
over-estimate the true extent of a CNV’s boundaries [47]. Thus,
we expect enhanced resolution of pathogenic CNVs to also
increase the power by which genic enrichments can be identified.
However, it should also be noted that CNVs have been shown to
affect the expression of neighbouring genes and it is possible that
pathogenic CNVs may exert their genetic effect through outlying
genes [48].
Finally, there is no reason why this approach can not be applied
successfully to other complex neurological diseases, including
schizophrenia and autism, which show a high frequency of rare de
novo CNVs [8,9,49–51]. Many studies that are currently under-
powered to demonstrate significance after correcting for multiple
testing may yet prove informative of the genetic etiology of
complex genomic disorders. For this, it will be crucial to collect
large disease-associated CNV sets from well-phenotyped cohorts,
as our analysis has shown that only then is there sufficient power to
detect significant associations (Figure S2).
Materials and Methods
Rare de novo CNVs in mental retardation
For this study we collected 148 rare structural variants
associated with MR from the literature, the Decipher database
(https://decipher.sanger.ac.uk/), as well as from our own in-house
diagnostic microarray group [52] (Table S1). The majority of these
CNVs (n=135, 91%) were proved to have occurred de novo in the
patient and all were independently validated. Thirteen rare
autosomal CNVs for which parental samples were unavailable
were included, as were seven rare maternally inherited CNVs on
the X chromosome in male patients that are considered to be as
clinically relevant as de novo CNVs on the autosomes. Importantly,
MGI phenotype or KEGG pathway Gene in Loss MR CNVR Gene in Gain MR CNVR
ESPN MAPT SLC25A12
GLI2 SCN1A ZMPSTE24
HD
These are present in MR–associated CNVRs and belong to any of three significantly enriched annotations; namely, mouse knockout phenotypes of abnormal
dopaminergic neuron morphology or abnormal axon morphology (Figure 1), and KEGG neurodegenerative pathway genes (Figure 2). Neurodegenerative pathway
genes within the Parkinson’s disease pathway are marked with an asterisk (‘*’). The remaining genes lie within CNVs associated with the particular secondary clinical
features and belong to significant enrichments identified as specific to those clinical feature.
doi:10.1371/journal.pgen.1000531.t002
Table 2. Cont.
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at the point of discovery none of these CNVs were known to
greatly (.50%) overlap with a collection of .15,000 CNVs
identified in healthy individuals as collected in the Database of
Genomic Variants version 3 (http://projects.tcag.ca/variation/).
All CNVs were mapped to NCBI35 coordinates. The median
number of Entrez genes within a CNV was 35. Overlapping
CNVs were merged to obtain a non-redundant set of 112 CNV
regions (CNVRs) totalling 440 Mb of unique sequence (14.3% of
the total NCBI35 human genome assembly; Table 1). CNVR sets
were also formed separately from Gain and from Loss CNVs
(Table 1). For 121 of the 148 CNVs, information regarding
distinct anatomical or physiological abnormalities presented by the
patient in addition to MR was available (Table S2). These clinical
features were used to form 7 non-exclusive groupings for
additional tests.
Benign CNV datasets
We obtained 25,196 CNVs identified in 270 individuals from
Redon et al. [11]. To these, we added 1,276 inherited CNVs
identified in 494 individuals with a 32 k BAC tiling path array.
This last set is described in Nguyen et al. [53] and, together with
the Koolen et al. [52] MR–associated CNV data, are available
from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) with accession number GSE7391. Combined, these
apparently benign CNVs represent 430 Mb of unique sequence
(14.0% of the total NCBI35 human genome assembly; Table 1). In
the absence of information suggesting that any of the individuals
present with MR, we conservatively assume that genes overlapped
by these apparently benign CNVs do not contribute to the MR
phenotypes.
Genomic data sets
Assignment of protein-coding genes depended upon the
particular analysis performed: for protein-coding gene counts
and the Gene Ontology analysis, we assigned genes to CNVs
according to Ensembl [54] (Ensembl mart version 37), whereas for
KEGG pathway and MGI analyses we assigned genes to CNVs
according to Entrez genes [55].
Mouse Genome Informatics (MGI) phenotype data
Information on human NCBI genes whose mouse orthologues’
disruption had been assayed were obtained from the Mouse
Genome Informatics (MGI) resource (http://www.informatics.jax.
org, version 3.54) [12–14]. We employed the MGI’s human/
mouse orthology and marker assignment to map MGI mouse
marker phenotypes to Human Entrez genes [55]. We mapped,
using unambiguous gene orthology relationships, 5,075 different
MGI phenotypic annotation terms to 4,999 human genes. We
considered all phenotypic annotations from all experimental
methodologies described within the MGI resource. While the
vast majority of these annotations are derived from the disruption
of mouse genes, some phenotypes were derived from experi-
ments in which mutant alleles are introduced into the mouse (e.g.
[56]). Nonetheless, we regard the phenotypic information from
these experiments as remaining informative of the biological
functions or pathways to which the gene contributes. It is noted,
however, that the phenotypes of all genes underlying the
phenotypic enrichments we report in this work (Figure 1 and
Figure 2; Table 2) were obtained through gene disruption
experiments.
The MGI phenotypic annotations are categorised non-exclu-
sively into 33 over-arching terms (Table S3). When examining
finer phenotypic terms beneath an over-arching term(s) we
considered only those finer terms that possessed at least 1% of
the genes annotated with the over-arching term(s). This allowed a
reduction in the number of tests performed thereby limiting
spurious and uninformative results. The phenotypes associated
with the Entrez genes overlapped by a given set of genomic regions
were compared to the frequency of that phenotype across the
whole genome. All p-values were obtained by application of the
hypergeometric test and were subject to a false discovery rate
(FDR) of ,5% [18] (see below). Given the large number of
phenotypic terms and the unrealistic assumption of terms’
independence when applying an FDR, application of this
significance threshold is likely to be conservative.
Linking mouse knockout phenotypes to patient
phenotypes
Many of the MR patients used in this study show additional
clinical features. We tested for associations between commonly
occurring non-MR clinical features in patients and a subset of
MGI phenotypes. We scored patients for the presence of 7
common features derived from the London Dysmorphology
Database [57]. These were: (i) seizures/abnormal EEG, (ii)
facial dysmorphism, (iii) cleft palate, (iv) heart, general abnormal-
ities, (v) eye abnormalities, (vi) brain, general abnormalities, and
(vii) urogenital system abnormalities. Patients were excluded
if specific phenotypic data were unavailable (all 19 cases from
the Decipher database). As these secondary clinical feature-
grouped CNVs were fewer in number than the entire set of
MR–associated CNVs, and therefore relatively diminished in
statistical power, the most relevant MGI phenotypic categories
were selected (from a total of 33; Table S3) in order to reduce the
number of tests. Two pairs of paralogous genes, DLX1 & DLX2
and SELE & SELP, contributed to the significant phenotypic
enrichments reported within the secondary clinical feature
grouped CNVs (Table 2). However, significant phenotypic
enrichments that these pairs of paralogues contributed to all
remained significant after removing one of the paralogous pairs
(p,0.05; single test). Nevertheless, we note that an increased
penetrance of a resulting phenotype might be expected if these
pairs of paralogues provided a degree of redundancy to one
another, and therefore the concurrent copy number variation of
both paralogues may prove even more significant than variation
involving only one [42].
Kyoto Encyclopedia of Genes and Genomes (KEGG)
Annotations of genes involved in neurodegenerative pathways
were obtained from KEGG [17]. KEGG genes were collated if
they belonged to KEGG Pathways section 5.3, namely Alzhei-
mer’s disease (KEGG pathway 05010), Parkinson’s disease
(KEGG pathway 05020), Amyotrophic Lateral Sclerosis (KEGG
pathway 05030), Huntington’s disease (KEGG pathway 05040),
Dentatorubropallidoluysian atrophy (KEGG pathway 05050) and
Prion Diseases (KEGG pathway 05060). KEGG genes were
mapped to NCBI Entrez genes using associations provided by
KEGG.
Tissue expression of genes
For human gene expression data, we used GNF’s gene atlas
data for the MAS5-condensed human U133A and GNF1H chips,
considering all 74 non-cancer tissues [16]. Expression levels were
mapped to LocusLink identifiers and to 11,594 Ensembl Ensmart
37 (NCBI35) genes using the annotation tables supplied by GNF.
To identify genes that are highly expressed in the brain we selected
those genes whose expression in the whole brain exceeded by 4-
fold their median expression in all other non-brain tissues after
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excluding cancerous tissues. This resulted in 435 genes (3.75%)
being classified as exhibiting strong expression in the brain relative
to other tissues. However, the significant enrichments reported in
the Results were also found when brain-specificity was redefined at
2-, 3-, 7-, 10-, 11-, 12-, 13-, and 14-fold expression in the brain
above the median across all other tissues.
Postsynaptic protein genes
A set of postsynaptic protein genes was obtained from Collins et
al. [58] and matched to human orthologues using Ensembl
Compara [59]. Over- or under-representation of these genes
within human CNVs was assessed using the hypergeometric
distribution and all human Ensembl genes as the background set.
Statistical tests
The significance of enrichments or deficits of genes associated
with particular MGI knockout phenotypes, genes involved in
KEGG neurodegenerative pathways, genes associated with
particular GO terms and brain-specific genes were evaluated
using hypergeometric tests. Where multiple tests were performed,
a False Discovery Rate (FDR) multiple testing correction was
applied to ensure a less than 5% likelihood of any significant term
being a false-positive [18]. Explicitly, an FDR correction was
applied when testing for enrichments of genes: (i) associated with
MGI phenotypic terms, (ii) belonging to individual KEGG
neurodegenerative pathways or (iii) annotated with Gene Ontol-
ogy terms (Figure S1). All other tests performed were single tests.
Calculation of the fold-enrichment within MR–associated
CNVs for the final set of 55 MR–associated candidate genes was
performed by random sampling. 1000 gene sets, matched in gene
number to that within the Loss MR–associated CNVRs, were
obtained by random sampling and the median expected number
of genes, 23 (std.dev.=4.6), annotated with one or more
significantly-enriched terms (Figure 1 and Figure 2) was recorded.
Given the 50 candidate genes within the Loss CNVRs, we thus
estimate a ,2.2-fold enrichment over the number expected by
chance.
Supporting Information
Figure S1 Gene Ontology Slim terms significantly enriched
among genes within MR–associated CNVRs. MR–associated
CNVR sets denoted ‘‘minus benign CNVs’’ have had genes
removed that are also overlapped by benign CNVRs showing the
same direction of copy number change (i.e. Gain or Loss) as its
overlapping MR–associated CNVR. We tested whether genes
within MR–associated CNVRs exhibit a bias towards specific
molecular and cellular functions using a reduced set of Gene
Ontology (GO) annotations, namely GOslim terms [15, 60].
Columns marked with an asterisk (‘‘*’’) are associated with
significant differences over expected values after application of an
FDR of 5%. The Gene Ontology Consortium’s [15, 60],
annotations mapped to Ensembl genes were obtained from the
Ensembl Ensmart 37 database [54,59]. To reduce the number of
terms examined and the loss of significance arising from multiple-
testing, only GOSlim terms (a subset of GO terms: 53 process, 41
function and 36 component terms) were considered. Of 9
significantly over-represented GOSlim terms, 7 were related to
DNA-binding, DNA metabolism or transcription regulation, with
nuclear localisation being the only cellular component significantly
enriched (p=3.461025). The remaining 2 over-represented terms,
Intracellular and Binding, could also be attributed to this DNA-
associated signal. Despite its small size, the Gain MR–associated
CNVR data set was significantly enriched in genes with nucleic
acid binding functions (+23%, p=561024) and transcription
(+26%, p=261023), as indeed was the Loss data set. By contrast,
benign CNV genes show significant tendencies to encode proteins
with roles in immunity and host defense [20,21].
Found at: doi:10.1371/journal.pgen.1000531.s001 (0.04 MB PDF)
Figure S2 A high percentage of the entire MR–associated CNV
set is required for the reported enrichments to reach significance; this
demonstrates the collective power of a community’s data set. Shown
is the percentage of CNVs required from the total number of CNVs
collated for this study (n=148) to reach significance for five
annotations: namely, the mouse orthologue’s knock-out phenotypes
of (i) ‘‘nervous system’’, (ii) ‘‘abnormal axon morphology’’ and (iii)
‘‘abnormal dopaminergic neuron morphology’’, together with (iv)
KEGGNeurogenerative disease and (v) Parkinson’s disease pathway
genes. For each of 13 different proportions of the entire CNV
dataset, we randomly sampled 100 sets of MR–associated CNVs.
We then recorded the number of sets at that particular coverage that
yielded a significant enrichment for each of the 5 annotations for Loss
CNVs. Crucially, the significant enrichment of the ‘‘nervous system’’
phenotype genes was obtained only, on average, with 99% (147/
148) of the CNVs. The two finer-scale MGI phenotypes, ‘‘abnormal
axon morphology’’ and ‘‘abnormal dopaminergic neuron morphol-
ogy’’ were obtained, on average, with ,65% and ,85% of the
CNVs, respectively, while the two KEGG disease pathway
enrichments gain significance at 45%–55% coverage. These results
illustrate the data set sizes required to confidently detect these signals
and hence the value of collating disparate data sets.
Found at: doi:10.1371/journal.pgen.1000531.s002 (0.05 MB PDF)
Table S1 Sources of MR–associated CNVs employed in this
study. For each of the 17 sources of CNVs, the publication,
number of CNVs obtained, experimental platform used to
discover the CNVs, along with the platform’s approximate
resolution, and the broadness of the phenotype of the patients
studied, are provided.
Found at: doi:10.1371/journal.pgen.1000531.s003 (0.09 MB PDF)
Table S2 MR patient phenotypes and their individual CNVs.
All CNVs used in this study are listed together with the clinical
features of the relevant patient. CNVs from Decipher are not listed
with clinical information as they do not refer to a specific
individual but to a collection. All CNVs are confirmed de novo
unless indicated with an asterisk (*). Note that the CNV
numbering is not sequential as 6 CNVs from Koolen et al. (Table
S1) were found later after further quality control checks to be
inherited and thus were removed from consideration. For
extended reference details, please see Table S1.
Found at: doi:10.1371/journal.pgen.1000531.s004 (0.20 MB PDF)
Table S3 Matching patients’ secondary clinical features to MGI
mouse phenotype categories. For each set of CNVs grouped by
secondary clinical features, the MGI phenotypic categories tested
against are shown with an ‘X’. As CNVs grouped by secondary
clinical features are subsets of the entire set of MR–associated
CNVs, we sought to limit the number of statistical tests performed
by considering only a subset of all MGI phenotypic terms. Thus,
one of us (BVD) selected the most relevant categories (from a total
of 33) of MGI phenotypic terms that only then were tested for
significant enrichments.
Found at: doi:10.1371/journal.pgen.1000531.s005 (0.13 MB PDF)
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